^
Association details:
| Biomarker: | PD-L1 expression |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | Jemperli (dostarlimab-gxly) (PD1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Evaluation of Programmed Death Ligand 1 (PDL1) Response to Treatment in Patient-derived Organoids and Immune-marker Positron Emission Tomography (PET) Scanning in Non-small Cell Lung Cancer (NSCLC)
Excerpt:
...The primary endpoint is the correlation between "treatment-induced change in PDL1 in PDOs which will be evaluated as the ratio of PDL1 positive cells before and after treatment using flow cytometry and multiplex immunofluorescence analysis" AND "changes in PET which will be evaluated as the percentage difference in PDL1-PET standard uptake volume (SUV) uptake in lesions from the baseline to on-treatment" using the formula for Spearman's rank correlation coefficient. ...
Trial ID:
Source:
Title:
Safety and Efficacy of Dostarlimab in Patients with Recurrent/Advanced Non-Small Cell Lung Cancer: Results from Cohort E of the Phase I GARNET Trial
Published date:
05/23/2022
Excerpt:
The median duration of response of 11.6 months (range: 2.8–19.4). Responses were observed in 2/24 (16.7%) patients with PD-L1 TPS <1%, 4/20 (20.0%) patients with PD-L1 TPS 1–49% and 2/5 (40.0%) patients with PD-L1 TPS ≥50%....Dostarlimab demonstrated promising antitumor activity in advanced/recurrent NSCLC that progressed following platinum-based chemotherapy, including across all PD-L1 subgroups, and has an acceptable safety profile.
DOI:
https://doi.org/10.1016/j.cllc.2022.05.013
Trial ID:
